Previous 10 | Next 10 |
MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patien...
MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular d...
Summary Heavy selloff following top-line data from the BeAT-HF trial, that failed to meet primary endpoint. Still, there were numerous secondary data that were positive. CVRX is subsequently submitting for label expansion for Barostim. Price needs to find equilibrium in order to...
Medical device maker CVRx ( NASDAQ: CVRX ) lost ~34% pre-market Tuesday after announcing that its BeAT-HF post-market phase trial for FDA-authorized heart failure therapy Barostim did not reach the primary endpoint with statistical significance. Barostim is an implantable device t...
MINNEAPOLIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular di...
CVRx, Inc. (CVRX) Q4 2022 Earnings Conference Call January 26, 2023 5:30 PM ET Company Participants Mike Vallie - Westwicke, ICR Company Nadim Yared - President and Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants ...
CVRx press release ( NASDAQ: CVRX ): Q4 GAAP EPS of -$0.51 beats by $0.05 . Revenue of $7.18M (+96.2% Y/Y) beats by $0.2M . Q1 2023 Outlook: The Company expects to report total revenue between $7.1 million and $7.5 million. 2023 Outlook: Total revenue betwe...
MINNEAPOLIS, Jan. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its f...
MINNEAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to rel...
MINNEAPOLIS, Jan. 09, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary ...
News, Short Squeeze, Breakout and More Instantly...
MINNEAPOLIS, July 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with ca...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...
MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of m...